Product category:
Pharmaceutical Processing News
News Release from: Frost and Sullivan | Subject: World Plant Molecular Farming Market
Edited by the Processingtalk Editorial
Team on 18 January 2005
Cost-effective biopharmaceutical
manufacturing
Using live plants as factories holds massive potential for cost-effective biopharmaceutical manufacturing, and the unofficial moratorium on transgenic crops in Europe is beginning to wain
Strategic analysis of the world plant molecular farming market: using plants as factories holds massive potential for cost-effective biopharmaceutical manufacturing The new 'Strategic Analysis of the World Plant Molecular Farming Market', reveals that the biopharmaceutical market generated revenues of USD 45.0 billion in 2004
This article was originally published on Processingtalk on 7 Feb 2003 at 8.00am (UK)
Related stories
The HIV/AIDS Therapies Market
While antiretroviral drugs in existing categories continue to be the mainstay of the HIV/AIDS therapies market in the United States, the development of new drugs offers exciting growth prospects
The European breast cancer pharmaceuticals market
The quest for a breast cancer wonder drug, and improved survival rates, continue to pump up business in the breast cancer pharmaceutical industry
It is likely to reach USD 98.2 billion by 2011.
Despite this soaring demand for biopharmaceuticals, little progress is being made toward the improving efficiency and reducing costs in conventional biomanufacturing processes using microbial or mammalian fermentation systems.
However, using transgenic plants as a production method for biopharmaceuticals has the potential to improve scaleability and yield, which will allow a dramatic reduction in biomanufacturing costs.
Further reading
Proteomics sample preparations markets
Integrated, customised, and validated research solutions for proteomics analyses and drug discoveries will fuel growth in the sample preparations market, according to the latest market resaerch report
Portfolio management in pharmaceutical market
Portfolio management carves a niche for itself in the resource-constrained pharmaceutical market, based on the need to identify and prioritise the most profitable projects in the R and D pipeline
Pharma rethinks traditional product marketing
A resurgent disease management sector will compel pharmaceutical companies to market products as constituents of packages of care, re-directing their sales efforts towards planners rather than doctors
"Using plants as factories to produce recombinant protein products is emerging as a cost-effective, high capability solution to the issue of production capacity," says Frost and Sullivan Research Analyst Phil Webster.
"Several companies are now investigating the potential of plant molecular farming, with the market consisting predominantly of small start-ups working independently, and large multinationals offering third-party services." Several major challenges must be overcome before plant molecular farming can take a significant share of the biopharmaceutical manufacturing industry.
Participants in this industry will have to deal with public perception issues, which are particularly unfavourable in Europe where transgenic crops cannot currently be grown for commercial purposes.
This is affecting the ability of small companies to obtain venture capital funding, a major challenge for an industry dominated by start-ups.
However, the unofficial moratorium on transgenic crops in Europe is beginning to wain, as more transgenic products are granted approval for market.
No products produced by plant molecular farming are currently available in this emerging market, but as the first ones approach launch around 2006, the regulatory climate is expected to ease as case studies are presented for approval.
With production platforms and enabling technologies already available, high initial market growth is possible.
The onus is now on product development divisions to commercially introduce therapeutic products.
The forecast increase in demand for biopharmaceuticals makes the plant molecular farming industry an exciting sector to be in.
"An aging population is driving the need for novel biopharmaceutical products for the treatment of more complex diseases.
There is currently a shortfall in biopharmaceutical manufacturing facilities, which leaves great market potential for biopharmaceuticals produced from plants," notes Mr Webster.
The Strategic Analysis of the World Plant Molecular Farming Market, a part of the F&S Biotechnology subscription, provides an overview of and outlook for the world biofarming market.
The analysis provides information on the world industry dynamics as well as world, North American, European, and Rest-of-World market dynamics.
It also offers strategic recommendations that enable companies to align their positioning strategies to benefit from the changing markets and obtain maximum return on investment.
• Frost and Sullivan: contact details and other news
• Email this article to a colleague
• Register for the free Processingtalk email newsletter
• Processingtalk Home Page
Search the Pro-Talk network of sites
